Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mixed cryoglobulinemia (MC) is a small-vessel systemic vasculitis characterized by the presence of cryoglobulins, immunoglobulin complexes that precipitate at low temperatures ( < 37 ºC) inducing the inflammatory process. The most frequent etiology is hepatitis C infection (HCV) (1). Rituximab (RTX), an anti-CD20 monoclonal antibody, has recently emerged as the treatment of choice for severe MC (2). We present a case of severe hepatitis C virus-induced MC that was controlled and maintained in remission with RTX for 26 months, a remarkable prolonged period of time.

Download full-text PDF

Source
http://dx.doi.org/10.4321/s1130-01082013000800009DOI Listing

Publication Analysis

Top Keywords

severe hepatitis
8
hepatitis virus-induced
8
mixed cryoglobulinemia
8
long-term remission
4
remission rituximab
4
rituximab patient
4
patient severe
4
virus-induced mixed
4
cryoglobulinemia mixed
4
cryoglobulinemia small-vessel
4

Similar Publications

High morbidity and mortality associated with human β-coronavirus (CoV) infection highlight the need to determine host responses to infection and develop anti-viral therapies. Gap junction intercellular communication (GJIC), particularly involving Connexin43 (Cx43), is vital for maintaining central nervous system (CNS) homeostasis, and disruption of GJIC is a well-documented pathogenic mechanism among β-coronaviruses. Specifically, murine β-coronavirus, mouse hepatitis virus (MHV-A59) inoculation in the mouse brain causes acute-stage CNS viral spread and chronic neuroinflammatory demyelination while causing pronounced downregulation of Cx43 at the acute stage, reflecting a critical role in CNS pathology.

View Article and Find Full Text PDF

Case Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer.

Front Oncol

August 2025

Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.

View Article and Find Full Text PDF

Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level.

Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022.

View Article and Find Full Text PDF

Background: Yellow fever virus (YFV) remains a re-emerging zoonotic threat in South America. While epizootics in free-ranging spp. are well-documented, little is known about YFV infection in other Neotropical non-human primates (NHPs), particularly in captive settings.

View Article and Find Full Text PDF

The role of personal protective equipment (PPE) in protecting against exposure to infectious agents and toxic chemicals is well-established. However, the global surge in PPE demand during the pandemic exposed challenges, including shortages and environmental impacts from disposable waste. Developing effective, scalable, and sustainable decontamination methods for the reuse of PPE is essential.

View Article and Find Full Text PDF